JDRF•News•Letting insulin pumps for type 1 diabetes shrink in size – by perfecting concentrated insulin
Letting insulin pumps for type 1 diabetes shrink in size – by perfecting concentrated insulin
Posted on 25 July 2016
An exciting new research project could enable insulin pumps to become much smaller – which would be great news for people with type 1 diabetes.
Miniaturising insulin pumps
Next-generation type 1 diabetes technology such as wearable devices and implants are critical future developments for people with the condition to keep healthy. Miniaturising devices such as insulin pumps will make them less intrusive, heavy and cumbersome, breaking down barriers to their use.
Cambridge-based biopharmaceutical firm Arecor Ltd announces today it will collaborate with JDRF on a project which will see a focus on perfecting a concentrated form of insulin. This would mean that a smaller vial is needed to hold the liquid in an insulin pump, allowing the whole pump to miniaturise.
Currently, concentrated insulin is too slow-acting when placed in the human body. But Arecor Ltd will work to perfect a concentrated insulin that acts at the same speed as currently available rapid-acting insulins for people with type 1 diabetes. It is hoped the dosing volume could be reduced five to 10-fold.
About Arecor Ltd
Arecor Ltd is based at the world-renowned Cambridge Science Park. The firm focuses on adapting proteins such as insulin. The new partnership will see Arecor Ltd and JDRF working closely together and JDRF will provide up to £680,000 over 12 months.
Dr Sarah Howell, Chief Executive Officer - Arecor Ltd
‘We are delighted to be partnering with JDRF as a leading global organisation in type 1 diabetes research.
‘This partnership will accelerate the development of Arecor’s reformulated, ultra-concentrated, rapid-acting insulin programme which is a critical unmet need in the drive towards the next generation of miniaturised insulin delivery technology.
‘Ultra-concentrated insulin is an important product component in our portfolio of next generation diabetes products.’
Karen Addington, Chief Executive of JDRF in the UK
‘Evidence shows insulin pumps can help people with type 1 diabetes live healthier for longer.
‘Allowing these pumps to become smaller would make them even better tools for everyone living with the disease, including small children.
‘We are delighted to partner and collaborate with Arecor.’
Learn more about type 1 diabetes treatments and technologies
To find out more about treating type 1 diabetes, including more about insulin pumps and other type 1 diabetes technologies, click the link below.
Keep up to date with the latest type 1 diabetes research, news and events from JDRF
Share this content
Keep up-to-date with our news and events
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.